- Innovative fixed-dose combination of Desloratadine and Montelukast offers stronger, longer-lasting relief from allergic rhinitis and urticaria
- Addresses India’s rising burden of allergy-related disorders with once-daily, dual-pathway therapy
- CMD Dr. Rajiv Modi: “Dlorfast-M embodies our mission to deliver accessible, effective, and innovative healthcare solutions”
NE HEALTH & BUSINESS BUREAU
AHMEDABAD, OCT 16
In a significant step forward in allergy management, Cadila Pharmaceuticals, one of India’s leading research-driven pharmaceutical companies, has launched Dlorfast-M Tablets, a dual-action fixed-dose combination therapy containing Desloratadine (5 mg) and Montelukast (10 mg).
The new formulation is indicated for the treatment of allergic rhinitis and urticaria, two chronic and increasingly prevalent conditions that cause symptoms such as recurrent sneezing, nasal congestion, itching, hives, and swelling — all of which can severely impact productivity, sleep quality, and overall quality of life.
Tackling India’s Growing Allergy Burden
In India, allergy-related disorders have been steadily rising over the past decade, driven by factors such as urban pollution, lifestyle changes, and genetic predisposition. Recognising this growing public health challenge, Cadila Pharmaceuticals developed Dlorfast-M as a comprehensive, dual-pathway therapy that targets both histamine and leukotriene mechanisms — two key mediators of allergic inflammation.
Dual-Action Mechanism for Superior Relief
The formulation’s first component, Desloratadine, is a potent and selective histamine H₁-receptor antagonist, which blocks histamine, the primary trigger responsible for itching, swelling, and other allergy symptoms. The second component, Montelukast, is a leukotriene receptor antagonist that prevents airway inflammation, smooth muscle contraction, and mucus overproduction by binding with high affinity to cysteinyl leukotriene receptors.
Together, these two agents work synergistically to provide broad-spectrum, longer-lasting symptom control — surpassing the efficacy of single-pathway antihistamines or leukotriene inhibitors.
Clinically Proven, Convenient, and Well-Tolerated
Clinical studies have demonstrated that the Desloratadine-Montelukast combination significantly improves respiratory and dermatological allergy symptoms while maintaining an excellent safety and tolerability profile. The once-daily oral tablet regimen enhances patient adherence, making it a practical choice for long-term therapy.
Dlorfast-M Tablets are indicated for adults and adolescents suffering from allergic rhinitis or urticaria and are to be taken once daily as a single tablet.
“Committed to Accessible and Innovative Therapies”
Commenting on the launch, Dr. Rajiv I. Modi, Chairman and Managing Director, Cadila Pharmaceuticals Limited, said: “With the launch of Dlorfast-M, Cadila Pharmaceuticals continues its mission to provide accessible, effective, and innovative therapies to patients. This dual-action formulation addresses both histamine and leukotriene pathways, offering superior symptom control and improving quality of life for people living with allergies.”
Strengthening Leadership in Respiratory and Allergy Care
Cadila Pharmaceuticals has a strong legacy in respiratory and allergy therapeutics, with a diversified portfolio addressing chronic and acute respiratory disorders. The launch of Dlorfast-M reinforces the company’s leadership in this domain and its commitment to advancing world-class, affordable healthcare solutions for patients across India and international markets.
With Dlorfast-M, Cadila Pharmaceuticals once again demonstrates its focus on science-led innovation, aiming to empower clinicians and patients alike in the fight against allergies — one tablet at a time.
